Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Exclusion Criteria

• •Uncomplicated skin and skin structure infections such as furuncles, minor abscesses
• •Infections associated with, or in close proximity to, a prosthetic device
• •Severe sepsis or septic shock
• •Known bacteremia at time of screening
• •ABSSSI due to or associated with any of the following:
• •* Suspected or documented gram-negative pathogens in patients with cellulitis/erysipelas or major cutaneous abscess that require an antibiotic with specific gram-negative coverage. Patients with wound infections where gram-negative adjunctive therapy is warranted may be enrolled if they meet the other eligibility criteria
• •* Diabetic foot infections, gangrene, or perianal abscess
• •* Concomitant infection at another site not including a secondary ABSSSI lesion (eg, septic arthritis, endocarditis, osteomyelitis)
• •* Infected burns
• •* Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease (arterial or venous)
• •* Any evolving necrotizing process (ie, necrotizing fasciitis)
• •Use of antibiotics as follows:
• •* Systemic antibiotic with gram-positive cocci activity for the treatment of any infection within 24 hours before the first infusion of study drug
• •* Patients who failed prior therapy for the primary infection site are also excluded from enrollment
• •* Topical antibiotic on the primary lesion within 24 hours before the first infusion of study drug except for antibiotic/antiseptic-coated dressing applied to the clean postsurgical wound
• •Administration of Linezolid within 30 days before the first infusion of the study drug
• •Recent history of opportunistic infections where the underlying cause of these infections is still active (eg, leukemia, transplant, acquired immunodeficiency syndrome \[AIDS\])
• •Previous exposure to Tedizolid Phosphate treatment